First Hawaiian Bank Decreases Position in Novo Nordisk A/S (NYSE:NVO)

First Hawaiian Bank lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 4.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,205 shares of the company’s stock after selling 1,024 shares during the quarter. First Hawaiian Bank’s holdings in Novo Nordisk A/S were worth $1,235,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO. Northern Trust Corp lifted its position in Novo Nordisk A/S by 0.5% during the 1st quarter. Northern Trust Corp now owns 2,330,848 shares of the company’s stock worth $121,926,000 after acquiring an additional 11,457 shares in the last quarter. Boston Partners boosted its position in shares of Novo Nordisk A/S by 4.0% in the 1st quarter. Boston Partners now owns 2,257,710 shares of the company’s stock worth $118,101,000 after purchasing an additional 87,878 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Novo Nordisk A/S by 2.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 2,005,391 shares of the company’s stock worth $104,902,000 after purchasing an additional 42,519 shares during the last quarter. Saratoga Research & Investment Management boosted its position in shares of Novo Nordisk A/S by 5.1% in the 1st quarter. Saratoga Research & Investment Management now owns 1,510,346 shares of the company’s stock worth $79,006,000 after purchasing an additional 73,054 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Novo Nordisk A/S by 7.8% in the 1st quarter. Wells Fargo & Company MN now owns 1,391,065 shares of the company’s stock worth $72,766,000 after purchasing an additional 100,782 shares during the last quarter. 7.16% of the stock is owned by institutional investors.

Shares of NVO stock opened at $50.74 on Friday. Novo Nordisk A/S has a 1 year low of $41.23 and a 1 year high of $52.83. The stock has a market cap of $127.05 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 2.21 and a beta of 0.60. The company has a current ratio of 1.04, a quick ratio of 0.66 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $49.52 and a 200 day simple moving average of $49.56.

The company also recently declared a Semi-Annual dividend, which will be paid on Tuesday, August 27th. Shareholders of record on Monday, August 19th will be given a dividend of $0.318 per share. The ex-dividend date of this dividend is Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 44.05%.

Several research firms have weighed in on NVO. UBS Group reiterated a “buy” rating and set a $355.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 target price on the stock in a research report on Tuesday, June 11th. Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 target price on the stock. in a research report on Thursday, June 20th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 target price on the stock in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $111.58.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

See Also: Cryptocurrencies

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.